Biomarkers of pancreatic cancer

Pancreatology

Volumn 11, Issue SUPPL. 2, 2011, Pages 14-19

  Hamada, Shin ^a   Shimosegawa, Tooru ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CA19 9; CEA; DUPAN 2; hENT1; MicroRNA; S100P

Indexed keywords

CA 19-9 ANTIGEN; CALCIUM BINDING PROTEIN; CALCIUM BINDING PROTEIN S100P; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; ASPIRATION BIOPSY; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SCREENING; CANCER SURGERY; CANCER TISSUE; CYTOLOGY; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HISTOPATHOLOGY; HUMAN; METABOLOMICS; PANCREAS BIOPSY; PANCREAS CANCER; PRIORITY JOURNAL; RELIABILITY; SALIVA ANALYSIS; SENSITIVITY ANALYSIS; TRANSCRIPTOMICS; TUMOR BIOPSY;

EID: 79953827771     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000323479     Document Type: Article

References (28)

1. Eckel F, Schneider G, Schmid RM: Pancreatic cancer: a review of recent advances. Expert Opin Investig Drugs 2006;15:1395-1410. (Pubitemid 44615288)
2. Herlyn M, Sears HF, Steplewski Z, Koprowski H: Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol 1982;2:135-140.
3. Volmar KE, Vollmer RT, Routbort MJ, Creager AJ: Pancreatic and bile duct brushing cytology in 1,000 cases: review of findings and comparison of preparation methods. Cancer 2006;108:231-238. (Pubitemid 44835770)
4. Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, Hansen M, Eloranta JJ, Bhakta V, Brentnall TA, Luttges J, Kloppel G, Lemoine NR: Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol 2005;166:81-92. (Pubitemid 40051662)
5. Turner BG, Cizginer S, Agarwal D, Yang J, Pitman MB, Brugge WR: Diagnosis of pancreatic neoplasia with EUS and FNA: a report of accuracy. Gastrointest Endosc 2010; 71:91-98.
6. de Wolf C, Jansen R, Yamaguchi H, de Haas M, van de Wetering K, Wijnholds J, Beijnen J, Borst P: Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther 2008;7:3092-3102.
7. Salek C, Minarikova P, Benesova L, Nosek V, Strnad R, Zavoral M, Minarik M: Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer. Anticancer Res 2009;29:1803-1810.
8. Zhang L, Farrell JJ, Zhou H, Elashoff D, Akin D, Park NH, Chia D, Wong DT: Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology 2010;138:949-957.e1-e7.
9. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M: Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 2010;6:78-95.
10. Lamerz R: Role of tumour markers, cytogenetics. Ann Oncol 1999;10(suppl 4):145-149.
11. Naghibalhossaini F, Yoder AD, Tobi M, Stanners CP: Evolution of a tumorigenic property conferred by glycophosphatidylinositol membrane anchors of carcinoembryonic antigen gene family members during the primate radiation. Mol Biol Cell 2007; 18:1366-1374. (Pubitemid 46626631)
12. Kawa S, Oguchi H, Kobayashi T, Tokoo M, Furuta S, Kanai M, Homma T: Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. Br J Cancer 1991;64:899-902.
13. Tsavaris N, Kosmas C, Papadoniou N, Kopteridis P, Tsigritis K, Dokou A, Sarantonis J, Skopelitis H, Tzivras M, Gennatas K, Polyzos A, Papastratis G, Karatzas G, Papalambros A: CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. J Chemother 2009;21:673-680.
14. Klapdor R, Bahlo M, Babinski A, Klapdor S: CA19-9 serum concentrations - analysis of the serum kinetics during first-line therapy of pancreatic cancer in relation to overall survival. Anticancer Res 2010;30:1869-1874.
15. Tanno S, Nakano Y, Sugiyama Y, Nakamura K, Sasajima J, Koizumi K, Yamazaki M, Nishikawa T, Mizukami Y, Yanagawa N, Fujii T, Obara T, Okumura T, Kohgo Y: Incidence of synchronous and metachronous pancreatic carcinoma in 168 patients with branch duct intraductal papillary mucinous neoplasm. Pancreatology 2010;10:173-178.
16. Kanno A, Satoh K, Hirota M, Hamada S, Umino J, Itoh H, Masamune A, Asakura T, Shimosegawa T: Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas. J Gastroenterol 2010;45:952-959.
17. Ohuchida K, Mizumoto K, Egami T, Yamaguchi H, Fujii K, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M: S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res 2006;12: 5411-5416. (Pubitemid 44497255)
18. Villanacci V, Cestari R, Giulini S, Cengia P, Missale G, Berenzi A, Rossi E, Bonardi M, Baiocchi L, Bassotti G: Immunocytochemical assessment of p53 protein to detect malignancy in increased cell-yield brush cytology from the biliopancreatic tree. Dig Dis Sci 2009;54:789-792.
19. Hashimoto Y, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, Fukuda E, Sueda T, Hiyama E: Detection of human telomerase reverse transcriptase (hTERT) expression in tissue and pancreatic juice from pancreatic cancer. Surgery 2008;143: 113-125. (Pubitemid 350266038)
20. Haab BB, Porter A, Yue T, Li L, Scheiman J, Anderson MA, Barnes D, Schmidt CM, Feng Z, Simeone DM: Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. Ann Surg 2010;251:937-945.
21. Miyazawa Y, Uekita T, Hiraoka N, Fujii S, Kosuge T, Kanai Y, Nojima Y, Sakai R: CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res 2010;70:5136-5146.
22. Ben QW, Wang JC, Liu J, Zhu Y, Yuan F, Yao WY, Yuan YZ: Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol 2010;17:2213-2221.
23. Loos M, Hedderich DM, Ottenhausen M, Giese NA, Laschinger M, Esposito I, Kleeff J, Friess H: Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 2009;9:463.
24. Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, Salmon I, Deviere J, Van Laethem JL: Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 2009;15:2913-2919.
25. Ashida R, Nakata B, Shigekawa M, Mizuno N, Sawaki A, Hirakawa K, Arakawa T, Yamao K: Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer. J Exp Clin Cancer Res 2009;28:83.
26. Rachagani S, Kumar S, Batra SK: MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett 2010;292:8-16.
27. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-10518.
28. Li A, Omura N, Hong SM, Vincent A, Walter K, Griffith M, Borges M, Goggins M: Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010;70:5226-5237.